Connect with us

Headlines

Eye Health Firm Raises $38M+

The company focuses on age-related macular degeneration.

mm

Published

on

HARRISBURG, PA — MacuLogix Inc., which equips eyecare professionals with the instrument, tools and education to diagnose and treat patients with age-related macular degeneration, has completed a financing round totaling $38.7 million.

The Series D was led by new investor Vivo Capital with participation from existing investors Fisk Ventures, Roche Venture Fund, Berwind Private Equity and Life Sciences Greenhouse of Central Pennsylvania. To date, MacuLogix has raised $51 million in venture funding plus $10 million in venture debt.

“AMD is the leading cause of adult blindness in the Western world because we haven’t had the technology or tools to effectively detect and manage this progressive, chronic disease – until now,” said William D. McPhee, president and CEO of MacuLogix. “Our company is determined to see AdaptDx functional testing become the standard of care, enabling eye care professionals to detect, treat and manage AMD earlier and more effectively.

“With this funding and the addition of Vivo Capital, we are fully backed by a strategic group of investors who support our company’s vision to eliminate blindness caused by AMD.”

Advertisement

This funding will be used to further expand the MacuLogix team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx automated dark adaptometer, both domestically and internationally. Joining the MacuLogix board of directors with this round of funding are Jack B. Nielsen, managing director of Vivo Capital; Nathan Dau, principal of Vivo Capital; and Carole Nuechterlein, head of Roche Venture Fund. The remaining board members are:

  • William D. McPhee, President and CEO, MacuLogix
  • Gregory R. Jackson, Ph.D., Co-founder and Chief Technology Officer, MacuLogix
  • Stephen L. Rose, Managing Director of Fisk Ventures, LLC
  • Ronald P. Thiboutot, Ph.D., SVP of Science and Technology, Life Sciences Greenhouse of Central Pennsylvania

“Maculogix is entering a rapid commercial expansion phase and is a very good fit for our investment strategy,” Nielsen said. “The AdaptDx is uniquely situated to help patients being diagnosed at an early stage of AMD and enable better and earlier monitoring and treatment of the disease.”

New Harbor Venture Partners acted as the exclusive placement agent in this transaction.

Since launching in 2014, INVISION has won 21 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

Advertisement

SPONSORED VIDEO

SPONSORED BY ALTERNATIVE AND PLAN B EYEWEAR

New “Auxiliary Skin” Transforms Eyewear into Seamless Sunglasses

Watch this video to see just how easy it is to slay the “frame and clip” dilemma with Alternative and Plan B Eyewear’s new Interface Collection. For more information, contact the company directly: customerservice@alternativeeyes.com or call (888) 399-7742.

Promoted Headlines

Headlines

Vision Biotech Firm Changes Name

The company focuses on gene therapy.

mm

Published

on

Ophthotech Corp., a biotech company focused on diseases of the eye, announced that it is changing its name to IVERIC bio Inc.

The change is part of a “transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases with unmet medical needs,” the company said in a press release.

The firm will trade on the Nasdaq Global Select Market under the new ticker symbol “ISEE.” Its new corporate website at www.ivericbio.com.

“We are excited about our re-branding and corporate name change reflecting our transition to a gene therapy focused company developing treatments for patients with orphan inherited retinal diseases,” stated Glenn P. Sblendorio, CEO and president of IVERIC bio. “We are executing a strategy that leverages our retinal expertise and provides a clear path forward with multiple orphan IRD gene therapy programs.

“We believe this is an important time for the Company as we advance our diversified pipeline of scientifically compelling gene therapy programs and explore new gene therapy opportunities for the treatment of orphan IRDs and generate value for our shareholders.”

Advertisement

Dr. Kourous A. Rezaei, chief medical officer of IVERIC bio,  said: “We believe that gene therapy is the ideal solution to treat patients with orphan inherited retinal diseases for which there are no treatment options available.

“Our goal is to partner with physicians to address this significant unmet medical need, prevent vision loss and transform the lives of our patients. We look forward to the exciting opportunities that lie ahead. Our clinical therapeutic programs continue to remain on track, with clinical data expected by the end of 2019 and 2020 for these programs. If data are positive for these programs, we may seek partnership opportunities for future clincal development.”

Continue Reading

Headlines

Eyewear Company Settles with VSP, Gets Reinstated in Network

VSP removed Aspex from its provider list in 2010.

mm

Published

on

RANCHO CORDOVA, CA – VSP Global and Aspex Eyewear Inc. announced that Aspex has agreed to pay a financial settlement to VSP Global.

Aspex Eyewear will be reinstated as an in-network frame provider under VSP’s vision care insurance policies.

Podcast: More Ways to Motivate Your Own Eyecare Business Team
INVISION Podcast

Podcast: More Ways to Motivate Your Own Eyecare Business Team

Podcast: Why Can’t We All Just Get Along?
INVISION Podcast

Podcast: Why Can’t We All Just Get Along?

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare
Try Not to Blink

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare

Financial terms of the settlement were not disclosed.

The settlement arises from several lawsuits filed by Aspex Eyewear against VSP and Marchon Eyewear, according to a joint statement from VSP and Aspex.

“While court rulings over several years have resulted in favorable decisions for VSP Global, we are nevertheless pleased with this agreement and the opportunity for our respective organizations to move forward,” said Thomas A. Fessler, chief legal counsel and general counsel of VSP Global.

Thierry Ifergan, executive vice president of Aspex Eyewear, said: “Aspex is happy to be reinstated as an in-network frame provider. We are excited to offer Aspex’s top fashion and innovative technologies to VSP’s members through their extensive network of eye care professionals.”

Advertisement

The Sacramento Business Journal has reported that VSP decided “to remove Aspex from its in-network provider list in 2010 after the Canadian eyewear company sued two VSP subsidiaries for patent infringement.”

Aspex then filed suit alleging “breach of contract, antitrust violations and unfair business practices” by VSP in connection with that decision, according to the Business Journal.

Continue Reading

Headlines

Optometry College Inaugurates President

He is the 13th person to serve in the role.

mm

Published

on

New England College of Optometry has inaugurated Dr. Howard B. Purcell as its president.

Purcell is the 13th president in the college’s 125 year history, according to a press release from the institution. He is a graduate of the program, continuing the legacy of his father, Saul Purcell, who graduated in 1954.

New England College of Optometry inaugurated Dr. Howard B. Purcell as its 13th president. Source: New England College of Optometry

The ceremony took place at the Edward Kennedy Institute for the U.S. Senate in Boston in a recreation of the U.S. Senate chamber. It was attended by over 200 people, including the president’s family, friends and former and current colleagues, student leaders, industry leaders and community representatives. Distinguished delegates included representatives from four optometry schools – Dr. Kevin Alexander (Marshall B. Ketchum University), Dr. Morris Berman (MCPHS), Dr. Mark Colip (Illinois College of Optometry) and Dr. David Heath (State University of New York College of Optometry).

Pano Yeracaris, MD, chairman of the board, said Purcell’s “enthusiasm, energy and commitment is matched by his vision and effectiveness as a leader.”

Cynthia P. Macdonald, great granddaughter of NECO founder August Klein, noted all the hats that Purcell must now wear.

“I know that each one of those hats will be woven from threads of knowledge and competence, care and compassion, diversity and inclusivity, respect and integrity,” Macdonald said. “These are the shining threads that together create the tapestry of the many generations of NECO family. The Klein Family Legacy is now entrusted to your care, Dr. Purcell, and I have no doubt it will be well tended.”

Purcell stepped into the role on July 1, 2018. Over the past nine months, he “has become indelibly connected to the NECO community,” according to the release.

Student Council President Monica Luo, class of 2020, described his immediate immersion into NECO.

“For an institution that feels so strongly about the creation and nurturing of meaningful bonds and relationships, President Purcell is the perfect fit,” Luo said. “In just his first few months, he made every effort to be present everywhere and to speak to everyone. … For every individual, he is open to listening and providing support. He is always present and always receptive.”

Purcell outlined his strategic priorities for the college to help “prepare today’s optometrists for tomorrow’s optometry.” His vision includes diversifying revenue; nurturing diversity, equity and inclusion; expanding continuing education and specialized degree programs; collaborating with industry; and finding ways to “best support and prepare our students for whatever changes may arise,” according to the release.

Continue Reading

Advertisement

Advertisement

Advertisement

Most Popular